أعرض في EDS

LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial

التفاصيل البيبلوغرافية
العنوان: LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
المؤلفون: V. Atkinson, Andrew Haydon, P.A. Ascierto, C. Robert, Christian U. Blank, A.C.J. van Akkooi, Matteo S. Carlino, A. M. M. Eggermont, Clemens Krepler, Stefan Suciu, Adnan Khattak, Andrey Meshcheryakov, Mario Mandalà, Michal Kicinski, Georgina V. Long, Sandrine Marreaud, Nageatte Ibrahim, S. Dalle, S. Puig Sarda, Shahneen Sandhu
المصدر: Annals of Oncology. 31:S1175
بيانات النشر: Elsevier BV, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Double blinded, Distant metastasis, Hematology, Pembrolizumab, Placebo, Complete resection, Internal medicine, medicine, Stage III melanoma, business
تدمد: 0923-7534
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1d8b1ef879e45f2be9d1838c6e269165Test
https://doi.org/10.1016/j.annonc.2020.08.2276Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........1d8b1ef879e45f2be9d1838c6e269165
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534